Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678590 | 0.80 | DNM1 (0.41) | TSHRSMN1; SMN2FDPSDNM1CA2 | |
| SCHEMBL4134938 | 0.76 | — | — | |
| SCHEMBL9368619 | 0.75 | — | — | |
| SCHEMBL3026952 | 0.75 | — | — | |
| SCHEMBL270381 | 0.75 | — | — | |
| SCHEMBL28182600 | 0.75 | DNM1 (0.38) | TSHRSMN1; SMN2FDPSDNM1CA2 | |
| SCHEMBL8603359 | 0.73 | — | — | |
| SCHEMBL4145243 | 0.72 | TSHR (0.33) | TSHRSMN1; SMN2 | |
| SCHEMBL4842062 | 0.71 | — | — | |
| SCHEMBL21367093 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939198-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939200-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TSHR 2895/4885SMN1; SMN2 1745/4885FDPS 2159/4885 |
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TSHR 3415/4885SMN1; SMN2 1327/4885FDPS 3054/4885 |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ADORA1, CXCR6, NR0B1 | TSHR 1269/4885SMN1; SMN2 1803/4885FDPS 3279/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | TSHR 3563/4885SMN1; SMN2 2258/4885FDPS 2914/4885 |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | ADORA1, SLC28A1, ADORA2A | TSHR 3960/4885SMN1; SMN2 986/4885FDPS 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.